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Diclofenac sodium is a Non-Steroidal Anti Inflammatory Drugs that if being taken orally have 
the side effects of peptic ulcers and undergone the first pass metabolism, and also included in the 
Biopharmaceutics Classification System class 2 which resulted in the low rate of dissolution. This 
study aims to determine the influence of particle size reduction on the dissolution rate of diclofenac 
sodium in the form of an FDOF dosage. The formation of diclofenac sodium nanoparticles is carried 
out by ionic gelation method using chitosan and sodium tripolyphosphate as a crosslinker in various 
ratios characterized by Particle Size Analyzer and Scanning Electron Microscopy, then it is 
incorporated into the form of an FDOF that were prepared by solvent casting method at a dose of 12.5 
mg using variations concentration of SSG as superdisintegrant and PEG 400 as plasticizer. From the 
research results, diclofenac sodium nanoparticles are formed in the ratio of chitosan-sodium 
tripolyphosphate 6:1, have a size of 804 nm and spherical-shaped. The best FDOF dosage formula is 
F8 containing HPMC E5 LV 35% as the film forming agent, SSG 8% as superdisintegrant and PEG 
400 10% as plasticizer.  FDOF formula containing diclofenac sodium nanoparticles has a slightly 
bitter taste, disintegration time less than one minute, surface pH around 7 (neutral), drug content that 
meets the requirements of the range of determination which is 93.24 ± 0.96, the cumulative amount of 
drug dissolved in the 28th minute is higher by 88.45% compared to FDOF containing diclofenac 
sodium raw material, which is only 70.0%. 
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Diclofenac sodium is a Non-Steroidal Anti inflammatory Drugs that if being taken orally have 
the side effects of peptic ulcers and undergone the first pass metabolism so that only 50% of active 
substances can achieve systemic circulation (Katzung et al., 2012; Sweetman, 2009) In general 
diclofenac sodium is available in the form of conventional oral tablets. One strategy to overcome the 
problems above is through the development of solid intraoral film-shaped dosage form that is a Fast 
Dissolving Oral Film (FDOF). The delivery system in this dosage form is when the film is placed on 
the tongue, it immediately dissolves without the help of drinking water, then the drug can be 
immediately released and dissolved in the saliva and directly absorbed through the oral cavity (pre-
gastric) to systemic circulation, so as to increase the patient's accessibility, especially those who have 
pathological history of peptic ulcers and swallowing difficulty (Ali et al., 2016; Ghorwade et al., 
2011).  
Based on the Biopharmaceutical Classification System, diclofenac sodium belongs to class II, 
which is a drug that has low solubility but high permeability (Karam, 2015; Wagh and Patel, 2010) 
and slightly difficult to dissolve in water (Anonymous, 2014, 2017). This leads to a low bioavailability 
of diclofenac sodium. Bioavailability is often associated with the rate of dissolution, a drug that has a 
low dissolution rate can result in a decrease in absorption rate especially in the gastrointestinal tract. It 
is a major challenge to be able to formulate diclofenac sodium into an FDOF dosage form due to the 
limitation of saliva volume to be able to dissolve a particular amount of drugs and the limitations of 
the absorption surface area in the intraoral cavity.  
 




Equation 1 indicates that the increase in dissolution rate will occur significantly when the 
surface area (A) and the saturated solubility (Cs) of the active substance are increased. The surface 
area depends on the size of the particle, the smaller the particle size will make the contact surface area 
towards solvent medium to be even larger (Davies and Amino, 1993). One effort to improve both is by 
forming nanoparticles. Nanoparticles according to the pharmaceutical field are drug compounds which 
in a certain way are made in nanometer size called nanocrystal or drug compounds encapsulated in a 
nanometer-sized carrier system called nanocarrier (Patravale et al.,2004). Nanoparticles aim to 
overcome the solubility of active substances that are insoluble, improving poor bioavailability, 
modifying drug delivery systems so that drugs can go directly to specific areas, increasing the stability 
of active substances from environmental degradation (enzymatic decomposition, oxidation, 
hydrolysis), improving the absorption of a macromolecular compounds, reducing the bitter taste and 
irritating effect of an active substances in the digestive tract (Mohanraj and Chen, 2007). 
In this study, the aim is to determine the effect of reduced diclofenac sodium particle size 
resulting from the formation of nanoparticles using the ionic gelation method, a method that utilizes 
ionic interactions between polycation and polyanion to form a nano-sized polyelectrolyte complex 
(Yeo and Kinam, 2007), which is then incorporated into an FDOF dosage form. Then the FDOF 
profile containing diclofenac sodium nanoparticles was compared to the FDOF containing diclofenac 
sodium raw material as an active ingredient based on the dissolution rate test results. 
 
MATERIALS AND METHOD  
Materials 
Diclofenac sodium (ex PT. Kimia Farma, Indonesia), hydroxypropylmethyl cellulose E5-LV 
(Wuhan Senwayer Century Chemical, China), Polyethylene glycol 400 and sodium starch glycolate 
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(Gujarat Overseas Inc., India), aspartame, menthol, chitosan, tripolyphoshate sodium, acetic acid 




Manufacture of diclofenac sodium nanoparticle 
Diclofenac sodium nanoparticles were made by ionic gelation using chitosan and sodium 
tripolyphosphate as nanoparticles forming agents in the ratio of 2:1, 3:1, 4:1, 5:1, 6:1 and 7:1. 
 
Preparation of chitosan solution 
Weighed chitosan was dissolved in 1% glacial acetic acid solution. 
 
Preparation of tripolyphosphate sodium solution 
Weighed sodium tripolyphosphate was dissolved in 20 mL demineralized aqua 
 
Preparation of  nanoparticle 
Diclofenac sodium weighed as much as 100 mg was dissolved in chitosan solution. 
Subsequently, the sodium tripolyphosphate solution was dropped into the mixture at room temperature 
(28 ± 2oC) under the rotation of the ultra-turrax homogenizer at a speed of 20000 rpm for 5 minutes 
and sonicated for 5 minutes until a nanoparticle suspension was formed. The nanoparticles obtained 
were frozen with liquid nitrogen and lyophilized for 12 hours to obtain dry diclofenac sodium 
nanoparticles using a freeze dryer (Bhumkar and Pokharkar, 2006). 
 
Characterization of diclofenac sodium nanoparticle 
Particle Size Analyzer (PSA) 
Determination of particle size  is carried out using a particle size analyzer (PSA) by dispersing 
diclofenac sodium nanoparticles in aquadest at a ratio of 1/100 (v/v). 
 
Scanning  Electron  Microscopy (SEM) 
The characterization of nanoparticles using SEM aims to see the morphology of the diclofenac 
sodium nanoparticles produced. 
 
Formulation and evaluation of FDOF  
Formula optimization  of  FDOF 
Base formula orientation was carried out to determine the optimum FDOF formula with the 
solvent casting method (Kalyan and Bansal, 2012) using variations in the concentration of SSG as a 
superdisintegrant and PEG 400 as a plasticizer to produce the best formula based on evaluating the 
weight, thickness and disintegration time  (Table 1). 
 





F1 F2 F3 F4 F5 F6 F7 F8 F9 
HPMC E5-LV 35 35 35 35 35 35 35 35 35 
SSG 4 4 4 6 6 6 8 8 8 
PEG-400 5 10 15 5 10 15 5 10 15 
Aspartame  2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
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Manufacture of FDOF 
The optimum base formula based on evaluation results was chosen to make FDOF preparations 
containing diclofenac sodium raw material and diclofenac sodium nanoparticles each at a dose 
(equivalent) of 12.5 mg (Table 2). 




HPMC E5-LV (%) 35 35 
SSG (%) 8 8 
PEG-400 (%) 10 10 
Aspartame (%) 2.5 2.5 
Menthol (%) 10 10 
Diclofenac sodium (mg) 12.5 - 
Diclofenac sodium nanoparticle (mg) - 12,5 
 
Evaluation of FDOF 
Evaluation of the final preparation includes organoleptic, weight diversity, thickness, 
disintegration time, surface pH, drug content and dissolution rate test. 
 
RESULT AND DISCUSSION  
Manufacture of diclofenac sodium nanoparticle 
In the manufacture of diclofenac sodium nanoparticles that did not experience precipitation 
occurred at a chitosan-sodium tripolyphosphate crosslinking ratio of 6:1. Precipitation that occur 
indicates a larger particle size. Precipitation is caused by interactions between chitosan and sodium 
tripolyphosphate which have reached stoichiometry, causing more crosslinking to form between them 
and produce insoluble complexes. 
 
Characterization of diclofenac sodium nanoparticle 
Particle Size Analyzer (PSA) 
The results of the characterization of nanoparticles using PSA showed a sample with a particle 
size of 804 nm, where the size of the nanoparticles ranged from 10 to 1000 nm (Nagarajan et al., 2015) 
(Figure 1). 
 
Figure 1. Particle size analyzer result of diclofenac sodium nanoparticle 
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Scanning Electron Microscopy (SEM) 
Characterization using SEM aims to see the morphology of the nanoparticles produced. SEM is 
used to observe grain boundaries, distribution, phase limits, evidence of mechanical deformation and 
chemical compositions that have magnifications up to 200.000x, can observe thicknesses from 200 Å 
to 0.5 μm (Ruíz,2015). The evaluation results show that diclofenac sodium nanoparticles have a 
spherical shape and tend to be homogeneous compared to pure diclofenac sodium observed at 800x 
magnification with particle sizes ranging from 500-800 nm (Figure 2). 
 
 
Figure 2. Morphology of powder by Scanning Electron Microscope (SEM) with 800x 
magnification : A. Pure diclofenac sodium; B. Diclofenac Sodium Nanoparticles 
 
Formulation and evaluation of  FDOF  
Optimization of FDOF formula 
Formula optimization is carried out to select and determine the best base for film formation 
from the aspect of diversity in weight, thickness and disintegration time. Based on the evaluation 
results of the formula optimization, F8 is the best formula because it has a coefficient of variance in 
the diversity of weights, thickness and disintegration time that is smaller than other formulas, so it can 
be concluded that F8 can provide films with good characteristics (Table 3). 
 










F1 41.586 ± 0.041 0.114 ± 0.00 57.44 ± 1.51 
F2 42.093 ± 0.075 0.114 ± 0.00 66.26 ± 3.94 
F3 42.963 ± 0.387 0.114 ± 0.00 85.21 ± 5,61 
F4 41.467 ± 0.005 0.114 ± 0.00 46.31 ± 0.56 
F5 42.383 ± 0.015 0.114 ± 0.00 57.36 ± 0.45 
F6 43.487 ± 0.032 0.114 ± 0.00 53.55 ± 0.48 
F7 42.003 ± 0.184 0.114 ± 0.00 32.58 ± 2.44 
F8 42.820 ± 0.125 0.114 ± 0.00 43.05 ± 0.40 
F9 43.103 ± 0.005 0.114 ± 0.00 53.39 ± 0.94 
 
Manufacture  of  FDOF 
After getting the best formula from the optimization results, two FDOF formulations were 
prepared, namely FDOF containing diclofenac sodium raw material (F8-A) and FDOF containing 
diclofenac sodium nanoparticles (F8-B) with each dose (equivalent) 12.5 mg. 
 
Final Evaluation  of  FDOF 
Organoleptic evaluation results, F8-B has a transparent colour, odorless and has a slightly bitter 
taste, better than F8-A which has an slightly transparent, odorless and bitter taste. This proves that 
diclofenac sodium nanoparticles can dissolve well when incorporated in a hydrophilic FDOF base and 
also improving its bitter taste (Table 4). 
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Shape  Colour Odor Taste  
F8-A Square Slightly transparent    Odor Bitter 
F8-B Square  Transparent Odorless Slightly bitter 
 
The results of testing the diversity of weights, thickness, disintegration time and surface pH in 
both FDOF preparations fulfilled the requirements (Table 5). Both F8-A and F8-B have a 
disintegration time less than 1 minute and a surface pH value of close to 7 (neutral). It is known FDOF 
with a basic or acidic pH can irritate the oral cavity when used so that it affects the comfort of the 
patients. This proves that the formation of nanoparticles in diclofenac sodium does not affect the 
degree of acidity and basicity. 
Table 5. Evaluation of FDOF 
Formula  Evaluation 




Disintegration Time  
(second) 
Surface pH Drug content  
(%) 
F8-A 42.7 ± 0.5 0.116 ± 0.003 34.50 ± 0.51 6.828 ± 0.12 120.3 ± 3.81 
F8-B 43.7 ± 0.9 0.111 ± 0.002 33.60 ± 0.92 6.952 ± 0.05 93.24 ± 0.96 
 
The drug content of F8-A was 120.3 ± 3.81 and F8-B was 93.24 ± 0.96 (Table 5). When 
referring to the requirements of diclofenac sodium content in the preparation that is equal to 90 - 110% 
with an SD value of not more than 6 (Anonymous, 2014; Irfan et al., 2016) then F8-B meets the 
requirements, while F8-A does not meet the requirements. F8-B meets the requirements because the 
active ingredient is diclofenac sodium in the form of nanoparticles so that the solubility in the water 
increases, the homogenization process becomes easier and faster in an FDOF base. F8-A is not eligible 
because diclofenac sodium solubility is rather insoluble in water and forms clumps that are difficult to 
be homogenized in an FDOF base, thereby affecting its distribution in the preparation. 
From the dissolution rate test results in the 28th minute, it was proven that FDOF containing 
diclofenac sodium nanoparticles had a cumulative amount of dissolved drug which was higher at 
88.45% compared to FDOF containing diclofenac sodium raw material, which was only 70.0% (Figure 
3). This is consistent with Noyes and Whitney's equations that an increase in the affinity of the system 
is due to an increase in the contact surface area at the same amount (Adeyeye at el, 2007). 
 
Figure 3. Curve ratio of the amount of dissolved substances to the time between FDOF 
containing diclofenac sodium raw material (F8-A) against FDOF containing 
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From the results of this study can concluded that diclofenac sodium nanoparticles were made by 
ionic gelation method with chitosan and sodium tripolyphosphate as a crosslinker at a ratio of 6: 1 
could produce a nanoparticles of 804 nm in size and spherical in shape. The best FDOF preparation 
formula is F8 containing HPMC E5 LV 35% as a film forming agent, SSG 8% as a superdisintegrant 
and 10% PEG 400 as a plasticizer. FDOF formula containing diclofenac sodium nanoparticles has a 
slightly bitter taste, disintegration time is less than one minute, surface pH is around 7 (neutral), drug 
content that meets the requirements of the range of determination which is 93.24 ± 0.96, the 
cumulative amount of drug dissolved in the 28th minute is higher by 88.45% compared to FDOF 
containing diclofenac sodium raw material, which is only 70.0%. 
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